Back to search
FDAFDA · Food and drugs·Recall number Z-3101-2024

Atellica IM CA 19-9 (250 Test)- In vitro diagnostic use in the quantitative measurement of the CA 19-9 tumor-associated antigen in human serum using the Atellica CI and Atellica IM Analyzers SMN:10995489

Published September 18, 2024 · Recall initiated: July 26, 2024

Summary

FDA records medical device Class II recall Z-3101-2024, published September 18, 2024 and initiated July 26, 2024. Recalling firm: Siemens Healthcare Diagnostics, Inc.; Status: Ongoing; Lot: UDI-DI: (01)00630414598161(10)55977535(17)20240914 Kit Lot: 55977535. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Siemens Healthcare Diagnostics, Inc.
Distributor
Worldwide - US Nationwide distribution
Lot
UDI-DI: (01)00630414598161(10)55977535(17)20240914 Kit Lot: 55977535
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Atellica IM CA 19-9 (250 Test)- In vitro diagnostic use in the quantitative measurement of the CA 19-9 tumor-associated antigen in human serum using the Atellica CI and Atellica IM Analyzers SMN:10995489 recalled?

Yes. FDA published recall Z-3101-2024 on September 18, 2024. Reported hazard: Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.

What should I do if I have this product?

Voluntary: Firm initiated · Letter